Manufacturing Novartis unveils North Carolina API plant as final piece of $23B US expansion BioSpaceThe new plant will give Novartis end-to-end capabilities centered on North Carolina, where it plans to have five facilities across three sites.Read full story pharminent May 1, 2026 (Last updated: May 1, 2026) BioSpace The new plant will give Novartis end-to-end capabilities centered on North Carolina, where it plans to have five facilities across three sites. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Amgen positions MariTide as potential ‘best monthly’ obesity drugNext: Pfizer, Arvinas join SERD club with Veppanu approval Related Stories Manufacturing FDA Warning Letter Hits Sanofi’s Genzyme Ireland Site pharminent July 8, 2026 Manufacturing Tanabe pens deal to sell plants to Towa in post-buyout pivot pharminent July 8, 2026 Manufacturing FDA Selects Seven for PreCheck Pilot to Advance Drug Manufacturing pharminent July 1, 2026
